Key Points
- Apogee CEO Michael Thomas Henderson sold 20,000 shares on April 8 at an average price of $82.58 for $1,651,600 under a pre‑arranged Rule 10b5‑1 plan, leaving him with 1,132,987 shares (a 1.73% ownership reduction).
- Henderson has made three other 20,000‑share sales in 2024 (Jan 14, Feb 11, Mar 11), totaling 80,000 shares sold at prices ranging from $63.35 to $82.58.
- Despite the insider selling, institutional investors own about 79.04% of APGE and analysts remain largely positive, with a consensus target price of $110.79 and multiple buy/strong‑buy ratings.
Apogee Therapeutics Inc. (NASDAQ:APGE - Get Free Report) CEO Michael Thomas Henderson sold 20,000 shares of the business's stock in a transaction dated Wednesday, April 8th. The stock was sold at an average price of $82.58, for a total value of $1,651,600.00. Following the sale, the chief executive officer owned 1,132,987 shares in the company, valued at approximately $93,562,066.46. This trade represents a 1.73% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.
Michael Thomas Henderson also recently made the following trade(s):
- On Wednesday, March 11th, Michael Thomas Henderson sold 20,000 shares of Apogee Therapeutics stock. The stock was sold at an average price of $74.78, for a total value of $1,495,600.00.
- On Wednesday, February 11th, Michael Thomas Henderson sold 20,000 shares of Apogee Therapeutics stock. The stock was sold at an average price of $63.35, for a total value of $1,267,000.00.
- On Wednesday, January 14th, Michael Thomas Henderson sold 20,000 shares of Apogee Therapeutics stock. The stock was sold at an average price of $81.11, for a total value of $1,622,200.00.
Apogee Therapeutics Trading Down 0.3%
NASDAQ:APGE opened at $86.27 on Friday. The stock's 50-day moving average is $72.90 and its 200-day moving average is $67.65. Apogee Therapeutics Inc. has a 1-year low of $28.60 and a 1-year high of $88.35. The stock has a market cap of $5.99 billion, a P/E ratio of -20.44 and a beta of 1.02.
Apogee Therapeutics (NASDAQ:APGE - Get Free Report) last announced its earnings results on Monday, March 2nd. The company reported ($1.03) EPS for the quarter, beating the consensus estimate of ($1.05) by $0.02. As a group, equities analysts forecast that Apogee Therapeutics Inc. will post -3.09 EPS for the current year.
Hedge Funds Weigh In On Apogee Therapeutics
A number of institutional investors have recently modified their holdings of APGE. T. Rowe Price Investment Management Inc. raised its position in shares of Apogee Therapeutics by 189,522.2% during the fourth quarter. T. Rowe Price Investment Management Inc. now owns 2,732,456 shares of the company's stock worth $206,246,000 after purchasing an additional 2,731,015 shares during the period. Janus Henderson Group PLC raised its position in shares of Apogee Therapeutics by 324.4% during the fourth quarter. Janus Henderson Group PLC now owns 2,062,604 shares of the company's stock worth $155,697,000 after purchasing an additional 1,576,626 shares during the period. Perceptive Advisors LLC raised its position in shares of Apogee Therapeutics by 72.4% during the fourth quarter. Perceptive Advisors LLC now owns 2,330,651 shares of the company's stock worth $175,918,000 after purchasing an additional 978,662 shares during the period. Wellington Management Group LLP raised its position in shares of Apogee Therapeutics by 24.1% during the third quarter. Wellington Management Group LLP now owns 4,723,701 shares of the company's stock worth $187,673,000 after purchasing an additional 917,991 shares during the period. Finally, UBS Group AG raised its position in shares of Apogee Therapeutics by 646.1% during the third quarter. UBS Group AG now owns 799,465 shares of the company's stock worth $31,763,000 after purchasing an additional 692,308 shares during the period. 79.04% of the stock is owned by institutional investors and hedge funds.
Analysts Set New Price Targets
APGE has been the topic of several analyst reports. Jefferies Financial Group reiterated a "buy" rating and issued a $95.00 target price on shares of Apogee Therapeutics in a report on Monday, February 2nd. Stephens initiated coverage on Apogee Therapeutics in a report on Tuesday, December 16th. They issued an "overweight" rating and a $95.00 target price on the stock. UBS Group upgraded Apogee Therapeutics to a "strong-buy" rating in a report on Wednesday, January 7th. Stifel Nicolaus set a $133.00 target price on Apogee Therapeutics in a report on Tuesday, January 6th. Finally, Canaccord Genuity Group upped their target price on Apogee Therapeutics from $89.00 to $130.00 and gave the company a "buy" rating in a report on Tuesday, March 24th. Two equities research analysts have rated the stock with a Strong Buy rating, ten have issued a Buy rating, four have assigned a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, Apogee Therapeutics currently has an average rating of "Moderate Buy" and a consensus target price of $110.79.
Check Out Our Latest Stock Report on APGE
About Apogee Therapeutics
(
Get Free Report)
Apogee Therapeutics, Inc is a clinical-stage biotechnology company dedicated to the discovery and development of novel small molecule therapeutics that selectively target the nuclear receptor RORγt, a master regulator of T cell-driven inflammatory pathways. By modulating RORγt activity, Apogee aims to offer an oral treatment option for patients with autoimmune and inflammatory skin disorders.
The company's lead candidate, APG-157, is an oral RORγt inverse agonist currently undergoing early-stage clinical evaluation for moderate to severe plaque psoriasis.
Featured Articles
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
